全文获取类型
收费全文 | 7813篇 |
免费 | 739篇 |
国内免费 | 53篇 |
专业分类
耳鼻咽喉 | 141篇 |
儿科学 | 390篇 |
妇产科学 | 216篇 |
基础医学 | 942篇 |
口腔科学 | 101篇 |
临床医学 | 761篇 |
内科学 | 1841篇 |
皮肤病学 | 189篇 |
神经病学 | 748篇 |
特种医学 | 463篇 |
外科学 | 1043篇 |
综合类 | 133篇 |
一般理论 | 4篇 |
预防医学 | 610篇 |
眼科学 | 115篇 |
药学 | 323篇 |
中国医学 | 1篇 |
肿瘤学 | 584篇 |
出版年
2023年 | 67篇 |
2021年 | 115篇 |
2020年 | 136篇 |
2019年 | 74篇 |
2018年 | 167篇 |
2017年 | 143篇 |
2016年 | 148篇 |
2015年 | 136篇 |
2014年 | 219篇 |
2013年 | 309篇 |
2012年 | 300篇 |
2011年 | 311篇 |
2010年 | 217篇 |
2009年 | 235篇 |
2008年 | 288篇 |
2007年 | 276篇 |
2006年 | 274篇 |
2005年 | 245篇 |
2004年 | 241篇 |
2003年 | 228篇 |
2002年 | 215篇 |
2001年 | 205篇 |
2000年 | 175篇 |
1999年 | 209篇 |
1998年 | 136篇 |
1997年 | 147篇 |
1996年 | 148篇 |
1995年 | 120篇 |
1994年 | 94篇 |
1993年 | 90篇 |
1992年 | 206篇 |
1991年 | 159篇 |
1990年 | 158篇 |
1989年 | 188篇 |
1988年 | 169篇 |
1987年 | 178篇 |
1986年 | 146篇 |
1985年 | 156篇 |
1984年 | 128篇 |
1983年 | 121篇 |
1982年 | 84篇 |
1981年 | 74篇 |
1980年 | 74篇 |
1979年 | 102篇 |
1978年 | 78篇 |
1976年 | 62篇 |
1974年 | 73篇 |
1973年 | 73篇 |
1972年 | 59篇 |
1971年 | 85篇 |
排序方式: 共有8605条查询结果,搜索用时 0 毫秒
1.
2.
3.
4.
5.
6.
Najat C Daw Wayne L Furman Clinton F Stewart Lisa C Iacono Mark Krailo Mark L Bernstein Janet E Dancey Rose Anne Speights Susan M Blaney James M Croop Gregory H Reaman Peter C Adamson 《Journal of clinical oncology》2005,23(25):6172-6180
PURPOSE: Epidermal growth factor receptor is expressed in pediatric malignant solid tumors. We conducted a phase I trial of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in children with refractory solid tumors. PATIENTS AND METHODS: Gefitinib (150, 300, 400, or 500 mg/m2) was administered orally to cohorts of three to six patients once daily continuously until disease progression or significant toxicity. Pharmacokinetic studies were performed during course one (day 1 through 28). RESULTS: Of the 25 enrolled patients, 19 (median age, 15 years) were fully evaluable for toxicity and received 54 courses. Dose-limiting toxicity was rash in two patients treated with 500 mg/m2 and elevated ALT and AST in one patient treated with 400 mg/m2. The maximum-tolerated dose was 400 mg/m2/d. The most frequent non-dose-limiting toxicities were grade 1 or 2 dry skin, anemia, diarrhea, nausea, and vomiting. One patient with Ewing's sarcoma had a partial response. Disease stabilized for 8 to > or = 60 weeks in two patients with Wilms' tumor and two with brainstem glioma (one exophytic). At 400 mg/m2, the median peak gefitinib plasma concentration was 2.2 microg/mL (range, 1.2 to 3.6 microg/mL) and occurred at a median of 2.3 hours (range, 2.0 to 8.3 hours) after drug administration. The median apparent clearance and median half-life were 14.8 L/h/m2 (range, 3.8 to 24.8 L/h/m2) and 11.7 hours (range, 5.6 to 22.8 hours), respectively. Gefitinib systemic exposures were comparable with those associated with antitumor activity in adults. CONCLUSION: Oral gefitinib is well tolerated in children. Development of the drug in combination with cytotoxic chemotherapy will be pursued. 相似文献
7.
8.
K. Wilhelmsen D. Mirel K. Marder M. Bernstein A. Naini S. M. Leal L. J. Cote M.-X. Tang G. Freyer J. Graziano R. Mayeux 《Annals of neurology》1997,41(6):813-817
The cytochrome P450 mono-oxygenase gene, CYP2D6 on chromosome 22q13 (ch22q13), has been inconsistently associated with Parkinson's disease. Associations with CYP2D6 have either been absent altogether or have involved more than one polymorphism, many of which have the same metabolic effect on gene expression. We examined the association between CYP2D6 polymorphisms and Parkinson's disease in a case-control study and included 10 polymorphic dinucleotide repeat markers linked to CYP2D6 to determine whether the association was present or due to linkage disequilibrium. There was no association between any polymorphism of CYP2D6 and Parkinson's disease, but two of 10 dinucleotide repeat markers linked to CYP2D6 were associated with the disease. These results provide evidence to suggest that there may be an unidentified locus for susceptibility to Parkinson's disease that is in linkage disequilibrium with dinucleotide repeat markers mapping near CYP2D6 on ch22q13. 相似文献
9.
10.
J. R. Bernstein B. M. Manzione R. C. Pohland R. B. Franklin 《Biopharmaceutics & drug disposition》1994,15(2):137-150
Tissue distribution studies, utilizing whole-body autoradiography and organ dissection techniques, were conducted in male Fischer 344 rats following the oral administration of 14C-dapoxetine HCl, a potent serotonin reuptake inhibitor. The preliminary study using whole-body autoradiography proved invaluable in locating radioactivity in an organ not usually harvested in a tissue distribution study, namely the preputial gland. Selected organs, based on whole-body autoradiography findings, were dissected from rats and analyzed for radiocarbon content by liquid scintillation counting and for parent drug and N-dealkylated metabolites by extraction and HPLC analysis. Highest concentrations of radiocarbon were observed in the organs of absorption and elimination (ileum, cecum, stomach, duodenum, liver, colon, and kidney) but notable quantities were observed in the lung and preputial and Harderian glands. Most tissues had returned to background radioactive levels 72 h after dosing but persistent concentrations of radiocarbon were present in the preputial gland and liver one week after the single dose of 14C-dapoxetine. Analysis by HPLC demonstrated the presence of parent drug and N-desmethyl metabolite (nor-dapoxetine) in those organs examined; however, the majority of the radioactivity remained unidentified. 相似文献